ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option

ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

BioPharma Dive

At a big meeting for weight loss drugs, Lilly s triple G therapy set a new standard as lingering doubts surrounded other competing treatments.

pharminent June 8, 2026 (Last updated: June 8, 2026)

BioPharma Dive

At a big meeting for weight loss drugs, Lilly s triple G therapy set a new standard as lingering doubts surrounded other competing treatments.

Related Stories